THE ECONOMICS OF ADJUNCTIVE THERAPIES IN CORONARY ANGIOPLASTY: DRUGS, DEVICES OR BOTH

Main Article Content

Dominic L. Raco

Keywords

abciximab, cost-effectiveness, percutaneous coronary intervention

Abstract

Oh and colleagues in Can J Clin Pharmacol Vol 11(2) Fall 2004:e202-e211; September 1, 2004 have provided a cost-effectiveness analysis (CEA) demonstrating that abciximab is more cost-effective than other commonly used therapies (for example, coronary artery stenting) and that it  should be more universally used in PCI patients.  The incremental cost-effectiveness ratio of $2,832 to $7,173 per life year gained with abciximab demonstrates greater value than almost any drug commonly used in cardiovascular medicine. Why then have physicians not routinely embraced abciximab?

Abstract 54 | PDF Downloads 26

References

1. Mark, DB, et al., Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996; 94(4): 629-35.
2. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
3. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo- controlled trial. Lancet 2000; 356: 2037-44.
4. Kini A, Marmur JD, Kini S et al. Creatine kinase- MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to- medium level elevation has a benign clinical course : Implications for early discharge after coronary intervention. J Am Coll Cardiol 1999; 34:3:663-671.